Split dose aspirin (ASA)

Phase 2Small molecule

TThomas Jefferson University

Split dose aspirin (ASA) is one of 4 small molecule programs targeting Aspirin. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AspirinRecruiting

AspirinPhase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Aspirin

#DrugCompanyPhaseTrials

Bayer Aspirin

Bayer

Approved

45 2

Acetylsalicylic Acid

Bayer

Phase 3

8 3

Celebrex

PPhiladelphia Eye Associates

Phase 1

2 4

Split dose aspirin (ASA)

TThomas Jefferson University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 1/2Recruiting

Aspirin

NCT06826859

Clinical

Trials by Indication[1]

Aspirin1 trial

Daily Aspirin vs Split Dosing in High-risk Pregnancies (DASH)

Recruiting·TThomas Jefferson University·Phase 1/2·NCT06826859·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Split dose aspirin (ASA). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Split dose aspirin (ASA) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Split dose aspirin (ASA). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Thomas Jefferson University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TThomas Jefferson University

Split dose aspirin (ASA)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Aspirin1 trial

References

Drug Info

Quick Facts

Related News